Published in J Neuroimmunol on February 03, 2009
Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol (2007) 16.81
A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity (2008) 5.89
Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood (2006) 5.05
A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol (2007) 4.63
Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med (2007) 3.51
Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat Genet (2007) 2.36
Jitter analysis with concentric needle electrode in the masseter muscle for the diagnosis of generalised myasthenia gravis. Clin Neurophysiol (2013) 1.49
Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes. Genome Res (2009) 1.42
Identification of novel genetic susceptibility loci for Behçet's disease using a genome-wide association study. Arthritis Res Ther (2009) 1.42
IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine (2005) 1.35
Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol (2005) 1.35
Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. Nat Genet (2013) 1.34
Analysis of significance patterns identifies ubiquitous and disease-specific gene-expression signatures in patient peripheral blood leukocytes. Ann N Y Acad Sci (2005) 1.28
The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev (2013) 1.21
Slow-channel mutation in acetylcholine receptor alphaM4 domain and its efficient knockdown. Ann Neurol (2006) 1.12
Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol (2010) 1.08
Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol (2003) 1.04
Confirmation of an association between rs6822844 at the Il2-Il21 region and multiple autoimmune diseases: evidence of a general susceptibility locus. Arthritis Rheum (2010) 1.04
Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet's disease. J Neuroimmunol (2011) 1.01
Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J Immunol (2002) 0.99
Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol (2005) 0.98
Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome. Cytokine (2008) 0.96
Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. J Neurol Sci (2013) 0.95
Epigenetics of multiple sclerosis: an updated review. Neuromolecular Med (2014) 0.95
ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS One (2012) 0.94
Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci (2010) 0.94
Complement and cytokine based therapeutic strategies in myasthenia gravis. J Autoimmun (2011) 0.94
Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Res Ther (2012) 0.93
Autoimmune thyroid encephalopathy presenting with epilepsia partialis continua. Clin EEG Neurosci (2006) 0.93
Non-convulsive status epilepticus associated with glutamic acid decarboxylase antibody. Clin EEG Neurosci (2013) 0.91
Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. J Clin Invest (2002) 0.89
Suppressive effect of bacterial polysaccharides on BAFF system is responsible for their poor immunogenicity. J Immunol (2011) 0.89
IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J Immunol (2005) 0.89
Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. J Immunol (2005) 0.88
Clinicopathological and genetic study of early-onset demyelinating neuropathy. Brain (2004) 0.88
Association of a serotonin receptor 2A gene polymorphism with cognitive functions in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2007) 0.87
Pro-inflammatory cellular immune response in Behçet's disease. Rheumatol Int (2007) 0.87
Human thyroglobulin peptide p2340 induces autoimmune thyroiditis in HLA-DR3 transgenic mice. J Autoimmun (2005) 0.87
Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun (2005) 0.86
HLA-DQ polymorphism in Turkish patients with myasthenia gravis. Hum Immunol (2006) 0.85
CACNA1H antibodies associated with headache with neurological deficits and cerebrospinal fluid lymphocytosis (HaNDL). Cephalalgia (2012) 0.85
Alternaria-induced release of IL-18 from damaged airway epithelial cells: an NF-κB dependent mechanism of Th2 differentiation? PLoS One (2012) 0.84
Brainstem encephalitis following influenza vaccination: favorable response to steroid treatment. Vaccine (2009) 0.84
Mitochondrial carrier homolog 1 (Mtch1) antibodies in neuro-Behçet's disease. J Neuroimmunol (2013) 0.84
Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis. J Neuroimmunol (2006) 0.83
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: favorable response to cancer treatment. J Spinal Cord Med (2012) 0.83
Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol (2011) 0.83
Complement C2 siRNA mediated therapy of myasthenia gravis in mice. J Autoimmun (2013) 0.83
GFPT1-myasthenia: clinical, structural, and electrophysiologic heterogeneity. Neurology (2013) 0.83
Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev (2013) 0.83
Comparison of the cytokine profiles of patients with neuronal-antibody-associated central nervous system disorders. Int J Neurosci (2012) 0.82
Antibodies to DNA repair proteins in headache with neurological deficits and cerebrospinal fluid lymphocytosis (HaNDL) patients. Acta Neurol Belg (2014) 0.82
Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J Neuroimmunol (2002) 0.82
The cDNA of mouse skeletal muscle transcribe for both isoforms 1 and 2 of acetylcholine receptor alpha subunit. J Neuroimmunol (2005) 0.82
fasciculations, autonomic symptoms and limbic encephalitis: a thymoma-associated Morvan's-like syndrome. Eur Neurol (2006) 0.82
A putative functional variant within the UBAC2 gene is associated with increased risk of Behçet's disease. Arthritis Rheum (2011) 0.82
Association of HLA-DRB1∗14, -DRB1∗16 and -DQB1∗05 with MuSK-myasthenia gravis in patients from Turkey. Hum Immunol (2013) 0.81
Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis. J Neuroimmunol (2006) 0.81
Alterations in cell-mediated immune response in subacute sclerosing panencephalitis. J Neuroimmunol (2005) 0.81
Anti-neuronal antibodies associated with headache with neurological deficits and cerebrospinal fluid lymphocytosis. J Headache Pain (2008) 0.81
ICOS is essential for the development of experimental autoimmune myasthenia gravis. J Neuroimmunol (2004) 0.81
Peripheral nerve hyperexcitability syndromes. Rev Neurosci (2015) 0.81
Targeting complement system to treat myasthenia gravis. Rev Neurosci (2014) 0.81
Sleep apnea in adult myotonic dystrophy patients who have no excessive daytime sleepiness. Sleep Breath (2009) 0.80
Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Ann N Y Acad Sci (2008) 0.80
Dendritic cells transduced with lentiviral-mediated RelB-specific ShRNAs inhibit the development of experimental autoimmune myasthenia gravis. Mol Immunol (2008) 0.80
Interleukin (IL)-12, IL-2, interferon-gamma gene polymorphisms in subacute sclerosing panencephalitis patients. J Neurovirol (2007) 0.80
Peripheral neuropathy associated with antiglutamic acid decarboxylase antibodies. Pediatr Neurol (2013) 0.80
Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol (2013) 0.80
Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol (2011) 0.80
Distribution of common CARD15 variants in patients with sporadic Crohn's disease: cases from Turkey. Dig Dis Sci (2006) 0.79
Cognitive impairment in neuro-Behcet's disease and multiple sclerosis: a comparative study. Int J Neurosci (2012) 0.79
Role of IL-5 during primary and secondary immune response to acetylcholine receptor. J Neuroimmunol (2002) 0.79
B cells produce less IL-10, IL-6 and TNF-α in myasthenia gravis. Autoimmunity (2014) 0.79
Induction of myasthenia gravis in HLA transgenic mice by immunization with human acetylcholine receptors. Ann N Y Acad Sci (2003) 0.79
Targeting classical complement pathway to treat complement mediated autoimmune diseases. Adv Exp Med Biol (2008) 0.79
Immunization of mice with T cell-dependent antigens promotes IL-6 and TNF-alpha production in muscle cells. Cytokine (2006) 0.79
Videothoracoscopic thymectomy for nonthymomatous myasthenia gravis: results of 90 patients. Surg Endosc (2007) 0.78
Early outcomes of video-assisted thoracoscopic resection of thymus in 181 patients with myasthenia gravis: who are the candidates for the next morning discharge? Interact Cardiovasc Thorac Surg (2009) 0.78
A new mouse model of autoimmune ocular myasthenia gravis. Invest Ophthalmol Vis Sci (2007) 0.78